Questcor Pharmaceuticals — Jefferies Healthcare Conference 2012
31 slides from Questcor Pharmaceuticals's conference presentation, Jun 6, 2012
Slide 1: Jefferies, June 6, 2012
NASDAQ: QCOR Exhibit 99.1 1 June 6, 2012 Jeffries NASDAQ: QCOR
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement 2 Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial perfor
Slide 3: A biopharmaceutical company whose product, Acthar, helps patients with serious conditions
3 A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions Questcor 3 A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions
Slide 4: Questcor Overview
4 Flagship Product: • Profitable, cash flow positive, $122M** in cash, debt-free • 19 approved indications Key Markets*: • Nephrotic Syndrome, Multiple Sclerosis, Infantile Spasms • Several billion dollar market opportunity Strategy: • Continue to grow Acthar sales in each key market • Develop Rheum
Slide 5: Questcor Strategy - Pursue Acthar Markets
5 5 Questcor Strategy - Pursue Acthar Markets Nephrotic Syndrome (NS) Multiple Sclerosis (MS) Infantile Spasms (IS) Rheumatology
Slide 6: Acthar and Nephrotic Syndrome (NS)
Acthar and Nephrotic Syndrome (NS) 6 • Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Acthar is approved “to induce a diuresis or a remission of proteinuria in the nephrotic syndrome
Slide 7: NS Scripts - Strong Continued Growth
Paid Rxs NS Scripts-Strong Continued Growth 7 Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of nephrotic syndrome, though the chart includes "Related Conditions" - diagnoses that are either alternative des
Slide 8: Acthar and Multiple Sclerosis (MS)
Neurodegenerative disorder Acute treatment for relapses Acthar and Multiple Sclerosis (MS) 8 43% get better or much better 27% get only a little better 30% stay the same or get worse ACTHAR is approved for MS exacerbations, without reference to first line or second line use but is generally position
Slide 9: MS Scripts - Record of Consistent Growth
Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely relat
Slide 10: Acthar and Infantile Spasms (IS)
• Devastating, refractory form of childhood epilepsy • Unsuccessful treatment may leave infant with permanent developmental disabilities • Ultra-rare orphan disorder • Acthar currently used to treat 40-50% of IS patients • Targeting select institutions Acthar and Infantile Spasms (IS) 10 • Devastati
Slide 11: Rheumatology
• 4 key indications on the Acthar label* – Systemic lupus erythematosus (Lupus) – Polymyositis/Dermatomyositis (PM/DM) – Psoriatic arthritis – Rheumatoid arthritis • High unmet need; difficult to treat • Serious health risk if unsuccessfully treated • Significant patient population (multi $B opportu
Slide 12: Financials
Profitable Debt Free Cash Flow Positive Financials 12 Profitable Debt Free Cash Flow Positive
Slide 13: Growth in Shipped Vials
Growth in Shipped Vials 13 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 Q1-10 Q2-10 Q3-10 Q4-10 Q1-11 Q2-11 Q3-11 Q4-11 Q1-12 Shipped Vials
Slide 14: Q1-2012 Financial Results
Q1 – 2012 Q1 – 2011 Q1-2012 Financial Results Record Net Sales (up 161%) and Solid Earnings (EPS up 241%) 14 Net Sales ($M) $96.0 $36.8 Gross Margin 94% 95% Operating Income ($M) $57.3 $16.4 Fully Diluted, GAAP EPS $0.58 $0.17 • First quarter vials shipped: 4,111 • First quarter cash flow from opera
Slide 15: April-May 2012 Metrics
• Paid Rxs April and May 2012 (estimated) • Shipped 1,560 vials in May 2012 – Compares to 1,350 vials in April 2012 and 4,111 vials in Q1-12 – Channel inventory level in the normal range on 5/31/2012 • Operating expenses expected to be up about $10 million in Q2-2012 over Q1-2012 and another $5 mill
Slide 16: Share Repurchases: 19.9 Million Shares
• 2.2 Million Preferred share buyback • 17.7 Common share buyback • $264 million returned to shareholders in stock buybacks – Average repurchase price per share: $13.23 • 59.6 million shares currently outstanding • 5.0 million share added to buyback authorization • 4.7 million shares remain on buyba
Slide 17: 2012 Repurchase Activity
• 4.5M shares repurchased during 2012, driven by: – Sales/EPS increase – NS market traction – Sales force expansion – Rheumatology opportunity 2012 Repurchase Activity Repurchased shares significantly improved EPS Q1-2012 EPS accretion from share repurchase through 3/31/2012: 24% 17 • 4.5M shares re
Slide 18: How Does Acthar Work?
How Does Acthar Work? • Acthar treats autoimmune conditions across a variety of organ systems (CNS, kidney, etc.) • Acthar appears to modulate the immune system and associated inflammatory response through binding to melanocortin receptors • The primary melanocortin peptide (ACTH) in Acthar binds to
Slide 19: Biosimilar Pathway Difficult/Impossible
• Difficult/impossible to reverse engineer ACTHAR – Not well characterized • Complex pharmacology – Not well characterized • Clinical trial(s) required Biosimilar Pathway Difficult/Impossible 19 • Difficult/impossible to reverse engineer ACTHAR – Not well characterized • Complex pharmacology – Not w
Slide 20: Total $3B+ Acthar Market Opportunity
Market Rx Value Market Size* Total $3B+ Acthar Market Opportunity 20 MS $40-50K $1B+ NS $150-250K $1B+ IS $100-125K $100M Rheumatology Various $1B+ Other Various Unknown *Based on company estimates
Slide 21: NS Business Already Significant
21 Market Approximate Annualized Net Sales Run Rate* Approximate Annualized Level of Business** NS Business Already Significant MS $160-175M $160-175M NS $125-140M $165-180M IS $40-50M $40-50M Note: Figures do not represent actual net sales ranges for the quarter ended March 31, 2012 * Figures based
Slide 22: Strategic Plan - Focus on the Embedded Pipeline in Acthar
22 • Expand NS promotion effort • Expand MS promotion effort • Maintain IS promotion effort • Initiate pilot rheumatology promotion activity • Develop other markets for Acthar • No unrelated business development efforts planned Strategic Plan- Focus on the Embedded Pipeline in Acthar • Expand NS pro
Slide 23: Sales Force Expansion - Outlook for 2012
23 Sales Force Expansion- Outlook for 2012 Q1-12 Q2 Q3 Q4 Q1-13 Rheumatology Sales Pilot Neuro Hiring & Training From 77 to 109 reps Neuro Sizing & Alignment Neph Hiring & Training From 28 to 58 reps Neph Sizing & Alignment Q1-12 Q2 Q3 Q4 Q1-13
Slide 24: Understanding Acthar: the science of how it works
24 • Generating more data for on-label indications – NS – MS – IS – Rheumatology • Investigating Acthar in potential new indications – Diabetic nephropathy – Autism – Traumatic brain injury – ALS – Migraine Over 40 Acthar R&D and Investigator Initiated Research Studies Understanding Acthar: the scie
Slide 25: Investment Highlights
25 Investment Highlights 25 Acthar has sustainable competitive advantages-without FDA approval risk Acthar is approved for 19 indications-many in large markets with sizable unmet need Sales in NS and MS are growing, yet market penetration is low Developing new vertical market - Rheum High margins pr
Slide 26: Appendix - Jefferies, June 6, 2012
26 June 6, 2012 Jeffries NASDAQ: QCOR
Slide 27: ACTH is a Melanocortin Peptide Derived from POMC
27 Pro-opiomelanocortin (POMC) in the Pituitary ACTH is a Melanocortin Peptide Derived from
Slide 28: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes
28 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC1R Podocytes Renal Mesangial Cells Endothelial Cells (Glomerular, Tubular, Vascular) Tubular Epithelial Cells Macrophages Melanocyt
Slide 29: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes
29 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC3R CNS Macrophages MC4R Podocytes Renal Mesangial Cells (?) Endothelial Cells (Glomerular, Tubular) Tubular Epithelial Cells CNS MC
Slide 30: MOA of Acthar in NS
MOA of Acthar in NS Adapted From Gong 2011 Acthar, Melanocortin Peptides Acthar, Melanocortin Peptides
Slide 31: Monthly MS Scripts History
31 Monthly MS Scripts History Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the
Questcor Pharmaceuticals — Jefferies Healthcare Conference 2012 on 6ix